• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Accuray Incorporated filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    11/25/24 4:05:08 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care
    Get the next $ARAY alert in real time by email
    8-K
    false000113872300011387232024-11-212024-11-21

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): November 21, 2024

    ACCURAY INCORPORATED

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-33301

    20-8370041

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    1240 Deming Way

     

    Madison, Wisconsin

     

    53717-1954

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 608 824-2800

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

    Trading

    Symbol(s)

    Name of each exchange

    on which registered

    Common Stock, par value $0.001 per share

    ARAY

    The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    (a)
    Amended and Restated 2016 Equity Incentive Plan

    At the Annual Meeting of Stockholders of Accuray Incorporated (the “Company”) held on November 21, 2024 (the “2024 Annual Meeting”), the Company’s stockholders approved amending and restating the Company’s 2016 Equity Incentive Plan to increase the number of shares of the Company’s common stock available for issuance thereunder by 5,000,000 shares. A description of the Amended and Restated 2016 Equity Incentive Plan is set forth in the Company’s definitive proxy statement on Form 14A filed with the United States Securities and Exchange Commission on October 4, 2024 and is qualified in its entirety by reference to the full text of the Amended and Restated 2016 Equity Incentive Plan, a copy of which is being filed as Exhibit 10.1 to this Form 8-K.

     

    (b)
    Amended and Restated 2007 Employee Stock Purchase Plan

     

    At the 2024 Annual Meeting, the Company’s stockholders also approved amending and restating the Company’s Amended and Restated 2007 Employee Stock Purchase Plan to increase the number of shares of the Company’s common stock that may be issued thereunder by 2,500,000 shares. A description of the Amended and Restated 2007 Employee Stock Purchase Plan is set forth in the 2024 Proxy Statement and is qualified in its entirety by reference to the full text of the Amended and Restated 2007 Employee Stock Purchase Plan, a copy of which is being filed as Exhibit 10.2 to this Form 8-K.

     

    (c)
    Appointment of Principal Accounting Officer

     

    On November 21, 2024, the Company’s Board of Directors appointed Michael Murphy, 45, as the Company’s principal accounting officer, effective December 2, 2024. Mr. Murphy joined the Company in October 2024 as Vice President, Corporate Controller. Previously, from February 2024 to October 2024, he served as Vice President, Chief Accounting Officer and Treasury at Duluth Trading Company, an American workwear and accessories company, where he also served as Interim Chief Financial Officer, Vice President and Chief Accounting Officer from September 2023 to February 2024, Vice President and Chief Accounting Officer from September 2019 to August 2023 and Corporate Controller from December 2018 to September 2019. Prior to that, he served as Chief Accounting Officer at First Business Financial Services, Inc., a financial services company, from September 2015 to December 2018. Mr. Murphy began his career at KPMG LLP. Mr. Murphy received a Bachelor of Business Administration, Accounting and Finance as well as a Master of Accountancy, both from the University of Wisconsin-Madison.

     

    In connection with his appointment, Mr. Murphy will enter into the Company's standard indemnification agreement. Mr. Murphy will not receive any additional compensation in connection with her appointment. Mr. Murphy has no family relationships or related party transactions with the Company that would require disclosure under Items 401(d) and 404(a) of Regulation S-K in connection with her appointment.

     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

    At the 2024 Annual Meeting, the Company’s stockholders voted on five proposals as set forth below. The following is a brief description of each proposal submitted to a vote at the 2024 Annual Meeting, as well as the number of votes cast for and against, the number of abstentions, and the number of broker non-votes with respect to each proposal.

     

    Proposal No. 1: Election of Directors

     

    The stockholders elected each of the following persons as a Class III director of the Company to hold office until the Company’s 2027 Annual Meeting of Stockholders or until his or her successor is duly elected or appointed.

     

    Nominee

    For

    Against

    Abstain

    Broker Non-Votes

    James M. Hindman

    48,004,871

    6,794,026

    94,739

    23,800,193

    Suzanne Winter

    48,484,848

    3,015,001

    3,393,787

    23,800,193

     

    Proposal No. 2: Approval of Amendment to the Company’s 2016 Equity Incentive Plan

    2

     


     

    The stockholders approved the Company’s Amended and Restated 2016 Equity Incentive Plan, with 48,115,913 shares in favor, 6,656,453 shares against, 121,270 shares abstaining and 23,800,193 broker non-votes.

    Proposal No. 3: Approval of Amendment to the Company’s 2007 Employee Stock Purchase Plan

    The stockholders approved the Company’s Amended and Restated 2007 Employee Stock Purchase Plan, with 50,239,197 shares in favor, 4,541,642 shares against, 112,797 shares abstaining and 23,800,193 broker non-votes.

     

    Proposal No. 4: Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers

     

    The stockholders cast an advisory vote to approve the compensation of the Company’s named executive officers as follows: 50,868,587 shares in favor, 3,697,761 shares against, 327,288 shares abstaining and 23,800,193 broker non-votes.

     

    Proposal No. 5: Ratification of Independent Registered Public Accounting Firm

     

    The stockholders ratified the appointment of Grant Thornton LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2025, with 76,205,166 shares in favor, 2,271,887 shares against, 216,776 shares abstaining and no broker non-votes.

     

     

     

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits

    Exhibit No. Description

    10.1 Accuray Incorporated Amended and Restated 2016 Equity Incentive Plan and forms of award agreements thereunder

    10.2 Accuray Incorporated Amended and Restated 2007 Employee Stock Purchase Plan

    104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

    3

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ACCURAY INCORPORATED

     

    Dated: November 25, 2024

    By:

    /s/ Jesse Chew

    Jesse Chew

    Senior Vice President, Chief Legal Officer & Corporate Secretary

     

     

     

    4


    Get the next $ARAY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARAY

    DatePrice TargetRatingAnalyst
    2/13/2024$9.00Buy
    ROTH MKM
    6/23/2022$7.50Buy
    B. Riley Securities
    12/22/2021$7.50Buy
    Loop Capital
    More analyst ratings

    $ARAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chalke Sandeep

    4 - ACCURAY INC (0001138723) (Issuer)

    4/1/26 5:14:50 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    SVP, Chief Operations Officer Peralta Leonel converted options into 83,723 shares and covered exercise/tax liability with 28,969 shares (SEC Form 4)

    4 - ACCURAY INC (0001138723) (Issuer)

    3/3/26 4:10:14 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Director Mayer Steven F bought $30,878 worth of shares (54,875 units at $0.56), increasing direct ownership by 4% to 1,545,620 units (SEC Form 4)

    4 - ACCURAY INC (0001138723) (Issuer)

    2/23/26 4:10:08 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Accuray Appoints Paul Miele as Senior Vice President and Chief Commercial Officer

    MADISON, Wis., April 6, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY), a leading provider of radiation therapy systems for cancer treatment, today announced the appointment of Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026. Miele will join Accuray's executive leadership team and lead the company's global commercial organization as Accuray continues to advance its transformation and strengthen execution across its portfolio. "Paul brings deep global commercial leadership experience and a strong track record of driving transform

    4/6/26 9:00:00 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Accuray Reports Fiscal 2026 Second Quarter Financial Results

    MADISON, Wis., Feb. 4, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the second quarter ended December 31, 2025. Key Highlights  On December 15, 2025 the Company announced the first phase of comprehensive, strategic, operational, and organizational transformational plan, which is expected to improve annualized operating profitability by approximately $25 million and set the stage for revenue growth:Plan includes organizational realignment, rightsizing of cost structure, outsourcing, and sales enablement in order to enhance competi

    2/4/26 4:05:00 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Accuray to Report Second Quarter Fiscal 2026 Financial Results on February 4, 2026

    MADISON, Wis., Jan. 21, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the second quarter of fiscal year 2026, ended December 31, 2025, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on February 4, 2026. The conference call dial-in numbers are 1-833-316-0563 (USA) or 1-412-317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-855-669-9658 (USA) or 1-412-317-0088 (interna

    1/21/26 4:05:00 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    SEC Filings

    View All

    Accuray Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - ACCURAY INC (0001138723) (Filer)

    4/7/26 9:00:20 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Accuray Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ACCURAY INC (0001138723) (Filer)

    4/6/26 9:00:13 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Accuray Incorporated

    SCHEDULE 13G/A - ACCURAY INC (0001138723) (Subject)

    3/26/26 3:05:49 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mayer Steven F bought $30,878 worth of shares (54,875 units at $0.56), increasing direct ownership by 4% to 1,545,620 units (SEC Form 4)

    4 - ACCURAY INC (0001138723) (Issuer)

    2/23/26 4:10:08 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Director Mayer Steven F bought $103,797 worth of shares (195,125 units at $0.53), increasing direct ownership by 15% to 1,490,745 units (SEC Form 4)

    4 - ACCURAY INC (0001138723) (Issuer)

    2/20/26 4:10:06 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    CEO La Neve Stephen R. bought $19,410 worth of shares (20,000 units at $0.97) (SEC Form 4)

    4 - ACCURAY INC (0001138723) (Issuer)

    11/19/25 5:18:33 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Accuray with a new price target

    ROTH MKM initiated coverage of Accuray with a rating of Buy and set a new price target of $9.00

    2/13/24 6:29:42 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    B. Riley Securities initiated coverage on Accuray with a new price target

    B. Riley Securities initiated coverage of Accuray with a rating of Buy and set a new price target of $7.50

    6/23/22 7:25:39 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Loop Capital initiated coverage on Accuray with a new price target

    Loop Capital initiated coverage of Accuray with a rating of Buy and set a new price target of $7.50

    12/22/21 4:56:14 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    Financials

    Live finance-specific insights

    View All

    Accuray Reports Fiscal 2026 Second Quarter Financial Results

    MADISON, Wis., Feb. 4, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the second quarter ended December 31, 2025. Key Highlights  On December 15, 2025 the Company announced the first phase of comprehensive, strategic, operational, and organizational transformational plan, which is expected to improve annualized operating profitability by approximately $25 million and set the stage for revenue growth:Plan includes organizational realignment, rightsizing of cost structure, outsourcing, and sales enablement in order to enhance competi

    2/4/26 4:05:00 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Accuray to Report Second Quarter Fiscal 2026 Financial Results on February 4, 2026

    MADISON, Wis., Jan. 21, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the second quarter of fiscal year 2026, ended December 31, 2025, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on February 4, 2026. The conference call dial-in numbers are 1-833-316-0563 (USA) or 1-412-317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-855-669-9658 (USA) or 1-412-317-0088 (interna

    1/21/26 4:05:00 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Accuray Reports Fiscal 2026 First Quarter Financial Results

    MADISON, Wis., Nov. 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the first quarter ended September 30, 2025. Key Highlights  On October 20, 2025, the Company announced accelerated transformation efforts, including:Appointed Steve La Neve as President and Chief Executive Officer. He succeeds Suzanne Winter, who will retire after six years of service and remain in an advisory role through the end of November 2025.Appointed Steven F. Mayer, a member of the Board of Directors, as the Transformation Board Sponsor to lead the Compan

    11/5/25 4:05:00 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    Leadership Updates

    Live Leadership Updates

    View All

    Accuray Appoints Paul Miele as Senior Vice President and Chief Commercial Officer

    MADISON, Wis., April 6, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY), a leading provider of radiation therapy systems for cancer treatment, today announced the appointment of Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026. Miele will join Accuray's executive leadership team and lead the company's global commercial organization as Accuray continues to advance its transformation and strengthen execution across its portfolio. "Paul brings deep global commercial leadership experience and a strong track record of driving transform

    4/6/26 9:00:00 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Accuray Accelerates Transformation Efforts with Appointment of Experienced Executive Leaders to Drive Performance and Growth

    Industry Veteran Steve La Neve Named Chief Executive Officer Suzanne Winter to Retire as President and CEOCompany Appoints Steven F. Mayer as Transformation Board SponsorChan W. Galbato Nominated to Board of Directors MADISON, Wis., Oct. 20, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today announced it is engaging in a significant organizational, strategic, and operational transformation. To accelerate this work, the company's Board of Directors has appointed proven industry leaders with deep operational expertise to drive execution, strengthen performance, and enhance competitiveness. The transformation plan initiatives, most of which will be implemented during the current fisc

    10/20/25 9:20:00 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply—while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a

    6/30/25 11:02:00 AM ET
    $ARAY
    $CLRB
    $ERAS
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ARAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Accuray Incorporated

    SC 13G/A - ACCURAY INC (0001138723) (Subject)

    9/6/24 9:00:07 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Accuray Incorporated

    SC 13G - ACCURAY INC (0001138723) (Subject)

    2/13/24 4:56:01 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Accuray Incorporated (Amendment)

    SC 13G/A - ACCURAY INC (0001138723) (Subject)

    2/13/24 11:19:22 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care